Camlin Fine Sciences proposes preferential issue for Vinpai acquisition

Camlin Fine Sciences announced a Postal Ballot Notice on September 29, 2025, to seek shareholder approval for a preferential issue of equity shares. This issuance, totaling up to 4,106,181 fully paid-up equity shares at an issue price of ₹247.69 per share, aims to fund the acquisition of a majority stake (approximately 78.68%) in Vinpai through a share swap arrangement. The total consideration for this preferential issue is ₹1,017,059,971.89. The equity shares will be allotted to five investors as consideration for their shares in Vinpai, with individual allocations ranging from 347,263 to 1,271,855 shares.

The e-voting period for this resolution will commence on Tuesday, September 30, 2025, at 09:00 a.m. IST and conclude on Wednesday, October 29, 2025, at 5:00 p.m. IST. The company emphasized that this preferential issue is not expected to result in a change of control or alter the shareholding of any single allottee or group by more than 5% of the post-issue fully diluted share capital. The new equity shares will rank pari-passu with existing shares and will be listed on the BSE and NSE, subject to regulatory approvals.

The relevant date for determining the floor price, as per SEBI ICDR Regulations, is Monday, September 29, 2025. This acquisition aims to strengthen Camlin Fine Sciences' position in the natural alternatives to chemical additives market, leveraging Vinpai's expertise in algae, plants, mineral, and fibre-based functional ingredients.